Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial
| Autor: | Mohammadreza, Rafati, Hossein, Karami, Bita, Lashtoo-Aghaee, Bahareh, Lashtoo-Aghaee, Mojdeh, Dabirian, Razieh, Avan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Caspian Journal of Internal Medicine, Vol 13, Iss 1, Pp 61-69 (2022) |
| ISSN: | 2008-6172 2008-6164 |
| Popis: | Background: Beta-thalassemia major patients typically require chronic transfusion and iron-chelating agents to reduce serum iron overload. Osveral® is an available Iranian brand name of deferasirox used by majority of thalassemic patients. The aim of this study was to compare the efficacy of Osveral® vs. Exjade® in major beta- thalassemia patients. Methods: In this randomized clinical trial, all patients received a single daily dose of 30 mg/kg either of Osveral® or Exjade® for 6 months. Primary outcome was the mean of bimonthly changes in serum ferritin concentration and secondary outcomes included mean changes of heart and liver MRI T2* after a year. Results: Finally, 80 patients completed the study. The mean serum ferritin level at the end of sixth month significantly decreased in Osveral® and Exjade® groups (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|